China has surged into a dominant global biopharmaceutical position and now challenges U.S. supremacy in biotech innovation and drug supply chains, industry leaders confirm. In March 2026, Pfizer CEO Albert Bourla issued a stark warning that China’s rapid advancement in biotech “is no longer catching up—it is leading,” with 8 of the top 10 global research institutions now Chinese according to the 2025 Nature Index.
This shift marks a dramatic turnaround from just a decade ago when China’s pharmaceutical industry centered primarily on generics and active pharmaceutical ingredients (APIs). Today, China supplies up to 80 percent of the intermediates used worldwide to manufacture APIs, including antibiotics, cancer therapies, and HIV drugs critical to U.S. healthcare.
China’s Supply Chain Stranglehold Raises Alarm
The U.S. Pharmacopeia found nearly 700 medicines approved in the U.S. depend on chemicals produced solely in China—exposing America to significant strategic vulnerabilities. Former FDA Commissioner Scott Gottlieb warned the risk of “every drug made in China” is real if current dependencies continue unchecked.
While direct imports appear limited, the effective U.S. dependence is amplified by India’s own reliance on Chinese APIs, making disruptions from geopolitical tensions or pandemics an urgent national security concern. Since generics represent about 90 percent of U.S. prescriptions, supply chain resilience for essential medicines has become a high priority.
China Advances Rapidly Up the Innovation Ladder
China’s biopharmaceutical innovation pipeline soared to 30.5 percent of global new drug candidates in 2025, narrowing the gap with the U.S. to just 2.5 percentage points. Licensing deals surged as well: Chinese firms generated a record $135.7 billion in partnerships in 2025, nearly tripling the previous year’s total.
Chinese breakthroughs show growing quality and global impact. Pfizer paid a record $1.25 billion to license 3SBio’s PD-1/VEGF cancer immunotherapy, and Akeso’s ivonescimab outperformed Merck’s Keytruda for lung cancer progression-free survival in Chinese patients. Innovent’s dual-action mazdutide was also approved domestically for weight management and diabetes.
How China Built Its Biopharma Power
China’s rise stems from a deliberate, state-driven strategy initiated with 2015 reforms under Bi Jingquan, vastly speeding drug approvals and enforcing data integrity. The “722 Notice” forced withdrawal of dubious pending applications, cleaning the slate for innovation.
China joined global regulatory bodies and slashed drug-review times from nearly 28 months in 2015 to under 6 months for priority drugs by 2024. Clinical trial approvals dropped from 18.5 months to often mere weeks. The country now leads the world with over 7,100 clinical trials registered versus about 6,000 in the U.S.
Crucial to China’s model is the “whole-nation system” coordinating government, academia, and industry resources. Massive biotech parks in Shanghai, Suzhou, and Wuxi, backed by billions in funding and talent repatriation programs, form the backbone of this ecosystem.
Strategic Stakes for the U.S. and Global Health
China’s “fast and cheap” biotech model may democratize access to lifesaving treatments worldwide, expanding affordable care in low-income countries through affordable innovation and digital health tools. Chinese AI-driven tuberculosis screening tools are already in use across 40 countries, showcasing the global impact potential.
But expanding Chinese influence has prompted U.S. countermeasures. The BIOSECURE Act, tightened FDA scrutiny of China-only clinical data, and 100 percent Section 232 tariffs on patented drugs and APIs effective July 31, 2026, are designed to curb strategic dependence and slow Chinese market entry.
Chinese drugmakers face barriers to direct U.S. market access since many clinical trials have been restricted by patient geography, leading to regulatory rejection of key drugs. This has pushed Chinese firms to out-license innovations to Western partners while navigating a congested domestic market with razor-thin profit margins.
The Path Ahead: Managed Competition and Resilience
Experts urge the U.S. to pursue resilience over replication—scaling domestic production of critical generics, diversifying supply chains through allies like India and Mexico, and maintaining diplomatic channels to reduce risks of pharmaceutical weaponization by China.
For Beijing, expanding global public-good programs and further domestic reforms could sustain innovation momentum and ease regulatory mistrust. The global community must seek pragmatic cooperation frameworks through the WHO or G20 to balance innovation with access, avoiding new geopolitical fault lines in global health.
As China marches forward as a biotech superpower, the U.S. and its allies face urgent choices to secure supply chains and foster collaboration—ensuring that rapid biopharma advances benefit patients worldwide rather than sparking new divides.
